Glucagon-like Peptide-1 (GLP-1) Receptor Agonists and Glucose Dependent Insulinotropic Polypeptide (GIP) Receptor Agonist

Goal(s):

Promote cost-effective and safe step-therapy for management of type 2 diabetes mellitus (T2DM).

Length of Authorization:

• Up to 12 months

Requires PA:

All non-preferred GLP-1 receptor agonists and GLP-1 receptor + GIP receptor agonists. Preferred
products do not require PA when prescribed as second-line therapy in conjunction with metformin.

Covered Alternatives:

- Current PMPDP preferred drug list per OAR 410-121-0030 at www.orpdl.org
- Searchable site for Oregon FFS Drug Class listed at <u>www.orpdl.org/drugs/</u>

Approval Criteria				
1.	What diagnosis is being treated?	Record ICD10 code		
2.	Does the patient have a diagnosis of Type 2 diabetes mellitus?	Yes: Go to #3	No: Pass to RPh. Deny; medical appropriateness.	
3.	Will the prescriber consider a change to a preferred product? Message: Preferred products are evidence-based reviewed for comparative effectiveness and safety by the Oregon Pharmacy and Therapeutics (P&T) Committee.	Yes: Inform prescriber of covered alternatives in class	No: Go to #4	
4.	Has the patient tried and failed to meet hemoglobin A1C goals with metformin or have contraindications to metformin? (document contraindication, if any)	Yes: Approve for up to 12 months	No: Pass to RPh. Deny; medical appropriateness. Recommend trial of metformin. See below for metformin titration schedule.	

Initiating Metformin

1. Begin with low-dose metformin (500 mg) taken once or twice per day with meals (breakfast and/or dinner) or 850 mg once per day.

- 2. After 5-7 days, if gastrointestinal side effects have not occurred, advance dose to 850 mg, or two 500 mg tablets, twice per day (medication to be taken before breakfast and/or dinner).
- 3. If gastrointestinal side effects appear with increasing doses, decrease to previous lower dose and try to advance the dose at a later time.
- 4. The maximum effective dose can be up to 1,000 mg twice per day. Modestly greater effectiveness has been observed with doses up to about 2,500 mg/day. Gastrointestinal side effects may limit the dose that can be used.

Nathan, et al. Medical management of hyperglycemia in Type 2 Diabetes: a consensus algorithm for the initiation and adjustment of therapy. *Diabetes Care*. 2008; 31;1-11.

P&T Review: 10/22 (KS), 8/20 (KS), 6/20), 3/19, 7/18, 9/17; 1/17; 11/16; 9/16; 9/15; 1/15; 9/14; 9/13; 4/12; 3/11

Implementation: 1/1/23; 9/1/20; 5/1/19; 8/15/18; 4/1/17; 2/15; 1/14